Update: Amazon's Bid to Dismiss FTC Suit Denied by Federal Judge Read More...
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger selloff Wednesday. The stock was down 5.5% Wednesday morning, bringing the stocks losses to 13% since the market closed on Friday. The stumble in Moderna share price, Barron’s wrote Tuesday, comes as investors await updates on three key areas: the company’s experimental cancer vaccine being developed with Merck ; the respiratory syncytial virus vaccine the Food and Drug Administration is expected to approve in the next few days, and the avian flu virus circulating in domestic cattle.
Barrons.com•
